- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 68,32 | +0,86 % | Ionis Pharmaceuticals: Einblicke in die Wachstumsstrategie auf der TD Cowen Konferenz | ||
| CSPC PHARMA | 1,029 | +0,93 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) ... | ||
| SELLAS LIFE SCIENCES | 4,710 | +3,29 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,185 | -6,19 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,540 | -0,24 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 367,60 | +0,14 % | Suzhou Ribo Life Science Co., Ltd.: Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,001 | -98,75 % | ENZON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| OPUS GENETICS | 3,695 | +0,82 % | Opus Genetics, Inc.: Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 5,150 | +7,29 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,660 | +3,91 % | Galectin Therapeutics Inc.: Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March ... | NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,010 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer | MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026... ► Artikel lesen | |
| CGN MINING | 0,515 | 0,00 % | CGN Mining CFO Xu Junmei Steps Down, Li Jie Appointed As New CFO | ||
| NOVABAY PHARMACEUTICALS | 1,460 | 0,00 % | XFRA B9P1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNOVABAY PHARMACEUTICALS... ► Artikel lesen | |
| PHOTOCURE | 5,540 | +0,73 % | Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions | OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that... ► Artikel lesen |
NATTOPHARMA ASA gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.